News
Learn about side effects, cost, dosage, and more for Repatha (evolocumab). It’s a prescription drug used to treat high cholesterol or heart disease.
Repatha (evolocumab) will be sold in the UK at a cost of $6,780 per year, less than half the $14,100 Amgen is charging for the drug in the US, with the price in other EU markets typically below ...
Repatha (evolocumab) is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C, or 'bad' cholesterol, from the blood.
THOUSAND OAKS, Calif., Aug. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new analysis from the Repatha ® (evolocumab) cardiovascular outcomes study (FOURIER) that showed a ...
Contraindication: Repatha is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®.
THOUSAND OAKS, Calif., March 13, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from a Phase 3 study evaluating Repatha ® (evolocumab) in patients who were ...
THOUSAND OAKS, Calif., Sept. 15, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a new analysis of the cardiovascular outcomes study ...
THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha(®) (evolocumab), an innovative treatment for patients with high ...
Repatha® (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).1 Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to ...
It’s not known whether Repatha (evolocumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. It’s not known ...
Combined Data From FOURIER and FOURIER-OLE Studies Show Earlier, Longer Use of Repatha Reduces Total CV Events Analysis From Phase 2 OCEAN(a)-DOSE Study Shows Olpasiran Markedly Reduced Lp(a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results